


HLS Therapeutics®


Gilbert Godin | CEO
Tim Hendrickson | CFO

Q3 2022 Results Conference Call
November 10, 2022

Forward-looking statements

Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always using words or phrases such as “project”, “forecast”, “target”, “expect”, “seek”, “endeavour”, “anticipate”, “plan”, “estimate”, “believe”, “intend”, or stating that certain actions, events or results may, could, should, would, might or will occur or be taken, or achieved) are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of known and unknown risks and uncertainties which would cause actual results or events to differ materially from those presently anticipated. A number of factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements could vary materially from those expressed or implied by the forward-looking statements contained in this presentation. These factors should be considered carefully and prospective investors should not place undue reliance on these forward-looking statements. Although the forward-looking statements contained in this presentation are based upon what HLS currently believes to be reasonable assumptions, HLS cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, HLS does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances.

*** All figures in USD unless otherwise noted.**




HLS Therapeutics®

Gilbert Godin | CEO
Tim Hendrickson | CFO

Q3 2022 Results Conference Call
November 10, 2022

Vascepa: ~70% Canadians on public plans eligible for reimbursement

Catalysts now in place to drive Vascepa growth



Public payer coverage

~70% publicly covered lives eligible for Vascepa reimbursement, including:

Ontario, Quebec, Saskatchewan, New Brunswick and Northwest Territories

Private payer coverage

>95% privately covered lives eligible for Vascepa reimbursement

Salesforce expansion

>4x increase in target audience via co-promotion agreement with Pfizer


Canadian medical society endorsement

Vascepa included in the guidelines for Canadian Cardiovascular Society, Thrombosis Canada and Canadian Heart & Stroke Foundation

Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update

Vascepa: Prescription momentum growing

Weekly script data since launch



Québec

New Rx: **20% increase**

Total Rx: **10% increase**

4-week period ended October 28, 2022, compared to the prior 4-week period

Ontario

New Rx: **12% increase**

Total Rx: **5% increase**


4-week period ended October 28, 2022, compared to the prior 4-week period

Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update


Source: Weekly Rx, 2020 - 2022, IQVIA

Vascepa: growth outpacing other cardiovascular therapies

New Rx




Total Rx



Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update

Vascepa: Broadening the user base

Total Rx by Physician Group



Source: IQVIA


As market access increases, our strategy is to leverage the 4x expansion in physician audience to 10,000 with greater call frequency to create awareness, trial and adoption


33% of total Rx & 43% of new Rx prescribed by general practitioners in Q3

Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update

RESPECT-EPA: shows CV benefit consistent with REDUCE-IT® and JELIS

21.5%






26.6%


Trial funded by the Japanese Heart Foundation

27.5%



1.8g/day purified EPA significantly associated with decreased risk of events related to coronary artery disease

Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update



HLS Therapeutics®

Gilbert Godin | CEO
Tim Hendrickson | CFO

Q3 2022 Results Conference Call
November 10, 2022